Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 54 15 71
Papillomatosis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2615
MeSH 43 D010212
NCIt 49 C3713 C7440
SNOMED-CT 67 23730008 82049002
UMLS 71 C0030354 C0205875

Summaries for Papilloma

Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to squamous cell papilloma and intraductal papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Metformin and Bethanechol have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1078)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 34.9 TP53 KRT14
2 intraductal papilloma 34.6 TP63 KRT5 KRT14
3 bladder transitional cell papilloma 34.6 TP53 KRT20 CDKN1A
4 urinary bladder inverted papilloma 34.5 RB1 CDKN2A
5 inverted papilloma 34.5 TP53 KRT5 KRT20 KRT13 CDKN2A AMOT
6 frontal sinus inverted papilloma 34.5 KRT5 KRT13
7 subareolar duct papillomatosis 34.5 KRT8 KRT5
8 inverted transitional papilloma 34.5 KRT5 CDKN2A
9 skin papilloma 34.0 TP53 PTEN KRT14 KRT10 CDKN1A
10 oral cancer 33.3 TP53 KRT13 CDKN2A
11 anogenital venereal wart 33.2 UBE3A TP53 RB1 CDKN2A
12 penile cancer 33.1 TP53 PTEN CDKN2A
13 bladder benign neoplasm 32.6 RB1 KRT20 CDKN2A
14 palmoplantar keratoderma, epidermolytic 32.5 KRT5 KRT14 KRT10 FLG
15 keratosis, seborrheic 32.5 TP53 KRT5 KRT10 IVL CDKN2A
16 li-fraumeni syndrome 32.4 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
17 cervix uteri carcinoma in situ 32.1 TP53 RB1 CDKN2A
18 suppressor of tumorigenicity 3 32.0 UBE3A TP53 RB1 CDKN2A CDKN1A
19 cervical intraepithelial neoplasia 31.9 KRT8 IVL CDKN2A
20 anus cancer 31.5 UBE3A TP53 CDKN2A
21 in situ carcinoma 31.5 TP53 PTEN KRT8 KRT5 KRT14 CDKN2A
22 familial retinoblastoma 31.5 TP53 RB1 CDKN2A
23 squamous cell carcinoma 31.5 TP63 TP53 RB1 PTEN KRT13 IVL
24 transitional cell carcinoma 31.4 TP63 TP53 PTEN KRT8 KRT20 CDKN2A
25 cervical cancer 31.4 UBE3A TP63 TP53 RB1 PTEN KRT14
26 adenocarcinoma 31.3 TP53 RB1 PTEN KRT20 CDKN2A CDKN1A
27 cervical squamous cell carcinoma 31.2 TP63 TP53 KRT8 CDKN2A
28 oropharynx cancer 31.2 UBE3A TP53 PTEN KRT5 KRT14 CDKN2A
29 epidermodysplasia verruciformis 1 31.2 UBE3A TP53 RB1 KRT14
30 oral leukoplakia 31.2 TP63 TP53 CDKN2A
31 ductal carcinoma in situ 31.2 TP53 PTEN KRT8 KRT5 KRT14 CDKN2A
32 vulvar intraepithelial neoplasia 31.1 TP53 CDKN2A
33 esophagitis 31.1 TP53 IVL IL4 CDKN2A
34 bowenoid papulosis 31.1 FLG CDKN2A
35 verrucous carcinoma 31.1 TP53 PTEN KRT5 KRT10 CDKN2A
36 vaginal cancer 31.1 UBE3A TP53 CDKN2A
37 cholangiocarcinoma 31.0 TP53 PTEN KRT8 KRT20
38 papillary transitional carcinoma 31.0 TP53 KRT20
39 meningioma, familial 31.0 TP53 PTEN IGF2 CDKN2A AMOT
40 esophageal cancer 31.0 TP63 TP53 RB1 PTEN IGF2 CDKN2A
41 hard palate cancer 31.0 KRT5 KRT14 KRT13
42 keratosis 31.0 TP53 KRT5 KRT10 IVL FLG CDKN2A
43 skin carcinoma 31.0 TP53 KRT8 KRT20 IVL FLG CDKN2A
44 actinic keratosis 31.0 TP63 TP53 KRT20 FLG CDKN2A
45 nasopharyngeal carcinoma 31.0 TP53 PTEN KRT13 CDKN2A CDKN1A
46 intrahepatic cholangiocarcinoma 31.0 TP53 PTEN KRT20
47 breast fibroadenoma 30.9 TP53 KRT8 KRT14
48 bladder cancer 30.9 TP63 TP53 RB1 PTEN KRT8 KRT20
49 small cell carcinoma 30.9 TP53 PTEN KRT8 KRT20 CDKN2A
50 ameloblastoma 30.9 TP53 KRT8 KRT14

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

GenomeRNAi Phenotypes related to Papilloma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CDKN1A CDKN2A PTEN RB1 TP53 UBE2L3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CDKN1A CDKN2A PTEN RB1 TP53 TP63

MGI Mouse Phenotypes related to Papilloma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
2 cellular MP:0005384 10.35 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
3 digestive/alimentary MP:0005381 10.34 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
4 cardiovascular system MP:0005385 10.32 AMOT CDKN1A CDKN2A IFNAR1 IGF2 KRT8
5 mortality/aging MP:0010768 10.31 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
6 endocrine/exocrine gland MP:0005379 10.28 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
7 integument MP:0010771 10.27 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
8 embryo MP:0005380 10.25 AMOT CDKN1A CDKN2A IGF2 KRT8 PTEN
9 immune system MP:0005387 10.25 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
10 craniofacial MP:0005382 10.17 CDKN1A IGF2 IL4 KRT14 KRT5 RB1
11 no phenotypic analysis MP:0003012 10.07 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT5
12 liver/biliary system MP:0005370 10.06 CDKN1A CDKN2A IGF2 IL4 KRT8 PTEN
13 limbs/digits/tail MP:0005371 10.02 CDKN1A IGF2 KRT5 PTEN RB1 TP53
14 neoplasm MP:0002006 10.01 CDKN1A CDKN2A IFNAR1 KRT14 PTEN RB1
15 reproductive system MP:0005389 9.93 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
16 renal/urinary system MP:0005367 9.86 CDKN1A IFNAR1 IGF2 IL4 PTEN RB1
17 pigmentation MP:0001186 9.72 CDKN2A KRT14 PTEN RB1 TP53
18 respiratory system MP:0005388 9.61 CDKN1A CDKN2A IGF2 IL4 KRT14 PTEN
19 vision/eye MP:0005391 9.32 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14

Drugs & Therapeutics for Papilloma

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Bethanechol Approved Phase 4 674-38-4 2370
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Polihexanide Approved, Investigational Phase 4 28757-47-3
5
Cantharidin Approved, Investigational Phase 4 56-25-7
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
10
Dolutegravir Approved Phase 4 1051375-16-6 54726191
11
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
12
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
13 Muscarinic Agonists Phase 4
14 Hypoglycemic Agents Phase 4
15 Chlorhexidine gluconate Phase 4
16 Biguanides Phase 4
17 Disinfectants Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
20 MF59 oil emulsion Phase 4
21 Pharmaceutical Solutions Phase 4
22 Anti-Infective Agents Phase 4
23 Antiviral Agents Phase 4
24 Vaccines Phase 4
25 Anti-Retroviral Agents Phase 4
26
protease inhibitors Phase 4
27 HIV Protease Inhibitors Phase 4
28 Anti-HIV Agents Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Anti-Bacterial Agents Phase 4
32 insulin Phase 4
33 Insulin, Globin Zinc Phase 4
34 Cytochrome P-450 CYP3A Inhibitors Phase 4
35 HIV Integrase Inhibitors Phase 4
36 Integrase Inhibitors Phase 4
37
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
38
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
39
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
40
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
41
Histamine Approved, Investigational Phase 3 51-45-6 774
42
Azithromycin Approved Phase 3 83905-01-5 55185 447043
43
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
44
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
45
Promethazine Approved, Investigational Phase 3 60-87-7 4927
46
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
47
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
48
Zinc Approved, Investigational Phase 3 7440-66-6 32051
49
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
50
Cetuximab Approved Phase 3 205923-56-4 56842117 2333

Interventional clinical trials:

(showing 481, show less)
# Name Status NCT ID Phase Drugs
1 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
2 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Unknown status NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
3 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
4 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
5 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
8 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
9 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
10 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
11 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
12 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
13 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
14 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
15 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
16 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
17 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
18 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
19 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
20 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
21 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
22 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
23 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
24 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
25 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
26 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
27 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
28 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
29 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
30 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
31 An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea Completed NCT00157950 Phase 3
32 Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India Completed NCT00380367 Phase 3
33 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
34 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
35 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
36 A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls Completed NCT01254643 Phase 3
37 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
38 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
39 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
40 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene
41 A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
42 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
43 A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study). Completed NCT00092547 Phase 3
44 Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process Completed NCT00169494 Phase 3
45 Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years) Completed NCT00196924 Phase 3
46 Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
47 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
48 A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age. Completed NCT00122681 Phase 3
49 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
50 A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study Completed NCT00337818 Phase 3
51 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
52 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
53 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
54 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
55 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
56 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
57 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
58 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
59 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts, A Randomized Clinical Trial Recruiting NCT03158168 Phase 3 Candida Antigen;Zinc Sulfate
60 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Recruiting NCT03296397 Phase 3
61 Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts Recruiting NCT02750202 Phase 3
62 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Recruiting NCT02669459 Phase 3 Imiquimod
63 A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. Active, not recruiting NCT01969877 Phase 3 cetuximab;cisplatin
64 An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients Active, not recruiting NCT03525210 Phase 3
65 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Active, not recruiting NCT02733068 Phase 3
66 TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma Active, not recruiting NCT01855451 Phase 3 Cetuximab;Cisplatin
67 A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls Active, not recruiting NCT02834637 Phase 3 bivalent HPV vaccine;nonavalent HPV vaccine
68 A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women Active, not recruiting NCT02059499 Phase 3 imiquimod;fluorouracil
69 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
70 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
71 An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary Not yet recruiting NCT04189107 Phase 3 Dexamethasone;Placebo
72 Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia: a Randomised Controlled Trial - The NOVEL Trial Not yet recruiting NCT03979014 Phase 3
73 A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia Terminated NCT00529464 Phase 3
74 Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Withdrawn NCT01058317 Phase 2, Phase 3 Propranolol
75 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
76 Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02555800 Phase 2 Bevacizumab;Cidofovir
77 Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx Unknown status NCT00002454 Phase 2
78 Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load Unknown status NCT01654822 Phase 2 topical application cervical spray;topical spray on the cervix
79 Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III Unknown status NCT00060099 Phase 2
80 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
81 A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis Completed NCT00038714 Phase 2 SGN-00101
82 Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial Completed NCT00454181 Phase 2 Interferon-alpha
83 A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis Completed NCT00571701 Phase 2 celebrex (celecoxib);placebo
84 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
85 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
86 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
87 Ensayo clínico, Aleatorizado, Abierto, de Grupos Paralelos y Con Grupo Control, Para Explorar la Eficacia Del Gel PAPILOCARE en la reparación de la Mucosa cérvico-vaginal Con Lesiones Causadas Por VPH (Ensayo Clínico PALOMA) Completed NCT04002154 Phase 2
88 A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
89 A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) Completed NCT02482428 Phase 2 Investigational Treatment;Aldara
90 A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years Completed NCT01356823 Phase 2
91 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
92 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
93 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
94 A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options Completed NCT02128126 Phase 1, Phase 2 ISA101/ISA101b
95 HPV Clearance by Folic Acid Supplementation (FACT for HPV) Completed NCT00703196 Phase 2
96 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
97 A Randomised, Multicentre, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy, Safety and Tolerability of Three Dose Regimens of Topical Nitric Oxide in Patients With Anogenital Warts Completed NCT02015260 Phase 2 Topical NO;Placebo
98 A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Gardasil (Registered) (Hpv) Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged >=11 To <18 Years Completed NCT01461993 Phase 2
99 Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix Completed NCT00003017 Phase 2
100 A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus Completed NCT00154089 Phase 1, Phase 2 EM-1421
101 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Completed NCT00285207 Phase 2 placebo;A007
102 Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases Completed NCT00899574 Phase 2 Imiquimod
103 Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts Completed NCT01757392 Phase 2
104 A Randomized, Double-blind, Multi-centre, Placebo Controlled Phase II Clinical Study to Evaluate the Efficacy, Tolerance and Safety of an Aqueous Gel Containing an Antiviral, Directly Applied on the Cervix Exhibiting High Grade Intraepithelial Lesion. Completed NCT01303328 Phase 2 C1
105 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women Completed NCT00550589 Phase 2 cidofovir
106 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
107 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
108 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
109 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
110 Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001 Completed NCT00120848 Phase 2
111 A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL Completed NCT01957878 Phase 2
112 Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3 Completed NCT00054041 Phase 2
113 A Phase II Trial of Polyphenon E for Cervical Cancer Prevention Completed NCT00303823 Phase 2 placebo
114 A Prolongation of Phase II Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions Completed NCT02976987 Phase 2 Cidofovir
115 A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Completed NCT00596258 Phase 2 A-007
116 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
117 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
118 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
119 A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age) Completed NCT00231413 Phase 2
120 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
121 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
122 Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung Completed NCT00021333 Phase 2 cisplatin;paclitaxel
123 A Phase II Trial OF Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx Completed NCT00014118 Phase 2 carboplatin;paclitaxel
124 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
125 A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a &gt;1mm Melanoma on Initial Biopsy Completed NCT00003895 Phase 2
126 Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma Completed NCT00324415 Phase 2 cisplatin;fluorouracil
127 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
128 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
129 A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
130 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
131 A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer Completed NCT02797964 Phase 1, Phase 2 SRA737
132 Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection Recruiting NCT03351855 Phase 1, Phase 2
133 A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02207439 Phase 2 Nelfinavir (Viracept®) 1250 mg;FMISO
134 Ensayo clínico Aleatorizado, Abierto, Paralelo, Controlado, multicéntrico, Para Explorar la Eficacia Del Gel Vaginal Papilocare® en la reparación de la Mucosa Cervical Con Lesiones Causadas Por Virus Papiloma Humano de Alto Riesgo Recruiting NCT04199078 Phase 2
135 Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. Recruiting NCT03623646 Phase 2 Chemoradiotherapy arm;Immunotherapy + Radiotherapy arm
136 A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial. Recruiting NCT03944915 Phase 2 Carboplatin;Paclitaxel;Nivolumab;Hydroxyurea Pill;5-fluorouracil;Filgrastim Injection;Cisplatin
137 A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients Recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
138 A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy Recruiting NCT03735290 Phase 1, Phase 2 Pembrolizumab
139 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
140 A Phase II Study of Volume and Dose De-Intensification Following Transoral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma Recruiting NCT03729518 Phase 2
141 Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery Recruiting NCT02827838 Phase 2
142 Immunomodulation of Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) After Platinum Failure Recruiting NCT02718820 Phase 1, Phase 2 Docetaxel;Pembrolizumab
143 A Prospective Non-inferiority Trial of Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma Recruiting NCT03323463 Phase 2 Cisplatin;Carboplatin;5Fluorouracil
144 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
145 Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer Recruiting NCT03224000 Phase 2
146 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
147 A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer Recruiting NCT02178072 Phase 2 5-Azacitadine
148 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
149 Window of Opportunity Trial of Neoadjuvant ADXS 11-001 Vaccination Prior to Robot -Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma Recruiting NCT02002182 Phase 2
150 A Phase II Clinical Trial of PepCan Randomized and Double-Blinded to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions Recruiting NCT02481414 Phase 2
151 A Phase II Study of Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions Recruiting NCT03937791 Phase 2
152 A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03024489 Phase 1, Phase 2 Palbociclib;Palbociclib;Palbociclib;Palbociclib;Cetuximab
153 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
154 Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) Recruiting NCT03799445 Phase 2
155 A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts Recruiting NCT03981822 Phase 2
156 Related and Unrelated Donor Hematopoietic Stem Cell Transplant of DOCK8 Deficiency Recruiting NCT01176006 Phase 2 Fludarabine(Fludara, Berlex Laboratories);Cyclophosphamide(CTX, Cytoxan);Busulfan (Busulfex)
157 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement Active, not recruiting NCT02632344 Phase 2 Pembrolizumab
158 A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis Active, not recruiting NCT02859454 Phase 2 Avelumab
159 A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis Active, not recruiting NCT03707587 Phase 2 M7824
160 A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer Active, not recruiting NCT03162224 Phase 1, Phase 2 MEDI0457;Durvalumab
161 Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer Active, not recruiting NCT01898494 Phase 2 cisplatin;carboplatin
162 A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Active, not recruiting NCT03499795 Phase 2
163 A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies Active, not recruiting NCT01693783 Phase 2
164 An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial Active, not recruiting NCT02258659 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;carboplatin;paclitaxel;fluorouracil;hydroxyurea;cisplatin
165 Phase II Study of De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma Active, not recruiting NCT01530997 Phase 2 Cisplatin
166 Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
167 Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer Active, not recruiting NCT02784288 Phase 2 Carboplatin;Paclitaxel
168 Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase II Trial Not yet recruiting NCT04178174 Phase 2
169 A Phase II Study of E7 TCR T Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer Suspended NCT04015336 Phase 2
170 Voice-preserving Treatment of Laryngeal Papilloma Terminated NCT00592319 Phase 2 Celebrex
171 A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3 Terminated NCT01116245 Phase 2 Placebo Control
172 A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Terminated NCT02540928 Phase 2 AMG 319 hydrate;Placebo
173 A Phase II Study of Docetaxel/Cisplatin/5-Fluorouracil (TPF) Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Using a Modified Radiation Dose in Patients With Newly Diagnosed HPV Positive, Locally Advanced Squamous Cell Carcinoma of the Oropharynx Terminated NCT01221753 Phase 2 docetaxel;cisplatin;5-FU;cetuximab;carboplatin
174 Phase II Study to Evaluate the Efficacy and Toxicity of Multimodality Treatment With Induction Taxotere/Cisplatin?5-FU (TPF) Chemotherapy Followed by Concomitant Cetuximab and Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Terminated NCT00721513 Phase 2 cisplatin;docetaxel;fluorouracil
175 A Phase II Study of Transoral Robotic Surgery With Adjuvant Therapy for Surgically Resectable HPV-positive Oropharyngeal Cancer Terminated NCT02225496 Phase 2
176 Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders Terminated NCT01525927 Phase 2 chemotherapy
177 S0212: Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix Withdrawn NCT00072540 Phase 2 celecoxib
178 Carotenoid-Rich Diet Trial to Reverse CIN II Withdrawn NCT00003094 Phase 2
179 Expanded Phase II Trial of a Carrageenan-Containing Gel for Prevention of HPV Infection Withdrawn NCT02382419 Phase 2 carrageenan-containing gel
180 Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer Withdrawn NCT01953952 Phase 2 cisplatin
181 Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis Unknown status NCT02854761 Phase 1 EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
182 Random, Double Blind, Placebo Controlled Phase I Clinical Trials to Estimate the Safety and Preliminary Immunogenicity of Tetravalent Recombinant Human Papilloma Virus Vaccine (6,11,16,18 Type)(Hansenula Polymorpha) in Women of 9 to 30 Years Old and Men of 9 to 17 Years Old Unknown status NCT02888418 Phase 1
183 A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects Unknown status NCT00493545 Phase 1
184 A Pilot Study for the Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) Pulsed With Human Papillomavirus Type 16 E7 Antigen Unknown status NCT00155766 Phase 1
185 Modulating the Expression of Oncoproteins of Papillomavirus (HPV) to Increase Radiosensitivity: a Phase I Study of Antiviral Agent Cidofovir and Chemoradiotherapy Therapy in Cervical Cancers Unknown status NCT00811408 Phase 1 carboplatin;cidofovir
186 A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children Completed NCT00001126 Phase 1 Cidofovir
187 A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold Completed NCT01020747 Phase 1 Avastin® (bevacizumab);Saline
188 A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL) Completed NCT03239223 Phase 1 ABI-1968
189 A Phase 1, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection Completed NCT00499967 Phase 1 GS-9191 ointment;GS-9191;Placebo
190 A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX) Completed NCT00851643 Phase 1
191 Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL) Completed NCT03202992 Phase 1 ABI-1968
192 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
193 A Pilot Study to Assess the Immunologic Response to Booster Vaccination With a Modified gp100 Melanoma Peptide (209-2M) Vaccine in Previously Vaccinated HLA-A2.1+ Patients With Melanoma Completed NCT01989559 Phase 1
194 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
195 VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER Completed NCT00019110 Phase 1
196 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
197 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
198 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
199 A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3) Completed NCT00989443 Phase 1 Cidofovir gel
200 Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus. Completed NCT01741012 Phase 1 Gardasil
201 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
202 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
203 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
204 A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults Completed NCT00798265 Phase 1
205 Infrared Coagulator For Treatment Of High Grade Squamous Intraepithelial Neoplasia (HSIL) in the Anal Canal In HIV Infected Individuals: A Pilot Study Completed NCT00066430 Phase 1
206 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
207 A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
208 A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol Completed NCT00004065 Phase 1 tanespimycin
209 PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION Completed NCT00002901 Phase 1 docetaxel
210 Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
211 Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies Completed NCT00045006 Phase 1 vorinostat
212 A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India Completed NCT00667563 Phase 1
213 An Open Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate 0.05% Gel for the Treatment of Verruca Vulgaris. Completed NCT02748902 Phase 1 ingenol mebutate 0.05% gel
214 A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
215 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
216 A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously in Combination With Montanide and GM-CSF on Immunological Response, Safety, Tolerability, and Preliminary Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck Completed NCT00257738 Phase 1
217 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
218 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
219 Phase 1 Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA) Completed NCT01485731 Phase 1 Nelfinavir;Cisplatin
220 STARS: Sistas Talking About Real Solutions Completed NCT01028157 Phase 1
221 Image Guided Surgery in Sinonasal Inverted Papilloma by Targeting Vascular Endothelial Growth Factor Recruiting NCT03925285 Phase 1 Bevacizumab-800CW
222 An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions Recruiting NCT03697226 Phase 1 Topical ABI-1968
223 A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females Recruiting NCT03900572 Phase 1 Placebo
224 A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) Recruiting NCT03100045 Phase 1 Artesunate Suppositories
225 A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting NCT03978689 Phase 1 CUE-101
226 Gemäßigte Ganzkörperhyperthermie Bei Patienten Mit Rezidivierten Plattenepithelkarzinomen Der Kopf-Hals Region Nach Hochdosierter Vorbestrahlung: Pilotstudie Zur Beeinflussung Des Tumormikromilieus. Recruiting NCT03547388 Phase 1
227 A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Recruiting NCT03529422 Phase 1 Durvalumab;Tremelimumab
228 HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
229 Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers Active, not recruiting NCT03618953 Phase 1
230 A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Not yet recruiting NCT02686008 Phase 1 Olaparib
231 A Phase I Study of Nelfinavir and Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Vulvar Cancer Not Amenable to Surgical Resection Not yet recruiting NCT04169763 Phase 1 Cisplatin;Nelfinavir
232 A Multicenter, Randomized Controlled Trial of 9-valent HPV Vaccination in Preventing Recurrence of High-grade Anal Dysplasia in HIV-positive MSM Not yet recruiting NCT03947775 Phase 1 9-valent HPV vaccination
233 Open-Label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Topical Abi-1968 In Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL) Terminated NCT03677960 Phase 1 Topical ABI-1968 cream
234 REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma Terminated NCT01598792 Phase 1
235 Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
236 A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn NCT02812056 Phase 1 Alisertib;TAK-228
237 Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
238 Screening for Human Papilloma Virus in Urine and Pap Smear.A Comparative Study. Unknown status NCT02613611
239 Recurrence After Surgery for Cervical Cancer - an Evaluation of the Follow-up Program. Unknown status NCT02096016
240 HPV Infection and Cervical Neoplasm in Women With Inflammatory Bowel Disease: a Cross-sectional Study Unknown status NCT03055130
241 The Thirty-six-Month Immunogenicity Evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years Unknown status NCT01427777
242 Acceptability and Feasibility of Human Papilloma Virus Vaccine Unknown status NCT01209338
243 A Model for the Implementation of the Cervical Cancer Screening and HPV Vaccination in the Emergency Department: a Pilot Study. Unknown status NCT01133509 Gardasil
244 Efficacy of a Combined Program for Early Detection of Breast and Gynecological Cancers in Low Resource Countries Unknown status NCT01178736
245 The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in CKD Patients Unknown status NCT01298869
246 Optimizing Cervical Cancer Screening Modalities and Identifying the Molecular Epidemiology of Human Papilloma Virus in Ethiopia: A Cluster Randomized Trial Unknown status NCT03281135
247 Experimentation of New Organizational Models of Cervical Cancer Screening Programs, Upon the Use of HPV Test as First Level: Evaluation of the Methodologies Proposed of the Use of Self-sampling Devices to Recover Non-responders. Unknown status NCT01647724
248 Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine (Gardasil) in HIV-infected Men Unknown status NCT00666107
249 Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities Unknown status NCT00501189
250 Topical 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Verruca Vulgaris: Comparison of Red and Green Light-Emitting Diode Array Unknown status NCT00155584
251 Randomized Implementation of Primary Human Papillomavirus (HPV) Testing in the Organized Screening for Cervical Cancer in Stockholm Unknown status NCT01511328
252 Prevaccination Distribution of Cervical Human Papillomavirus (HPV) Types and Their Associations With Invasive Cervical Cancer and Its Precursors in Yangtze River Delta Area, China Unknown status NCT01487681
253 "Performance of HPV DNA Test in Presence of Co-infection With Common RTIs" Unknown status NCT02830230 Tab cefixime,Tab Azithromycin
254 Nano-mechanical and Nano-electrosensing Devices Based Interaction Force and Interaction Kinetics Analysis of Oncogenic Human Papilloma Viruses Unknown status NCT01387997
255 Comparative Evaluation of Carbon Dioxide Laser and Cryotherapy by Dermoscopy in Treatment of Viral Wart Unknown status NCT03166137
256 Development and Application of a Multispectral Digital Colposcope and Probe Algorithm for Detection of Cervical Intraepithelial Neoplasia Unknown status NCT02406352
257 Evaluation of ELISA Assay on HPV Infection Population Unknown status NCT00673192
258 HPV as Primary Screening Test in Cervical Cancer Prevention: From DNA to mRNA? A Randomised Controlled Trial Nested in a Double Testing Study With Long Term Follow up Unknown status NCT01837693
259 Screening and Identification of Novel Diagnostic and Prognosis Biomarkers on Cervical Cancers Unknown status NCT00854269
260 Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems Unknown status NCT03188315
261 Infectious Risk of Vaginal Ultrasound Examination: Evaluation and Modeling From Human Papillomavirus (HPV) Unknown status NCT02659072
262 The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients Unknown status NCT00173394
263 The Development of Human Immunologic Assays Specific to Folate Receptor Antigen Unknown status NCT00155935
264 Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer in the County of Valles Occidental: CRICERVA Clinical Trial. Unknown status NCT01373723
265 Retrospective Trial to Assess HPV Epidemiology in Squamous Cell Carcinoma of Head and Neck Unknown status NCT01079546
266 The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being Unknown status NCT00155792
267 A Multi-Center, Randomized, Controlled Trial of the Pulsed Dye Laser for Juvenile Onset Recurrent Respiratory Papillomatosis Completed NCT00550914
268 Human Papillomatosis Genotyping and Severity in Patients With Recurrent Respiratory Papillomatosis of Children in Thailand Completed NCT01304966
269 Recurrent Respiratory Papillomatosis and Extraesophageal Reflux Completed NCT02592902
270 Human Papilloma Virus DNA Self-Test Completed NCT00266266
271 Post-Licensure Observational Study of the Safety of GARDASIL™ in Males Completed NCT01567813
272 Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions Completed NCT02217358
273 The Effects of Health Education About Human Papilloma Virus and Cervical Cancer Prevention on Knowledge, Attitudes, Beliefs and Behaviors of Adolescent Girls and Their Mothers: A Prospective Randomized Controlled Study Completed NCT04113902
274 Human Papillomavirus 6/11 in the Lower Airway of Neonates Completed NCT00549250
275 Evaluation of a Community-Driven Cervical Cancer Prevention Strategy in Western Kenya Completed NCT02124252
276 Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease in Women Undergoing Routine Cervical Cancer Screening Completed NCT00709891
277 Feasibility of a Twitter Campaign to Promote HPV Vaccine Uptake Among Racially/Ethnically Diverse Young Adult Women Living in Public Housing Completed NCT04023955
278 Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine (QHPV) to HIV-1 Infected Children Previously Enrolled in IMPAACT P1047 Completed NCT01206556
279 Acceptance of Human Papillomavirus Vaccination in Postpartum Women Completed NCT00730704
280 Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting Completed NCT00572832
281 HPV Infection in Indian HIV-Seropositive Men Who Have Sex With Men (MSM) Completed NCT00919997
282 Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System Completed NCT01446198
283 Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT03206255
284 Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity in Normal Women With Cytology Completed NCT03895905
285 A Feasibility Trial of Parent-targeted Strategies to Increase HPV Vaccination Completed NCT03987490
286 Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine: the AB-SOP Study Completed NCT02714114
287 Squamous Cell Carcinoma Antigen as a Marker of Sinonasal Inverted Papilloma Completed NCT01827423
288 Impact de la Vaccination Sur la Distribution Des génotypes de Papillomavirus (HPV) et Suivi de la Dynamique Intra-individuelle de l'Infection et Des Co-infections Dans Une Population d'étudiantes âgées de 18 à 20 Ans Completed NCT01988948
289 Effect of PI3K Inhibition in HPV-Associated HNSCC Completed NCT00897988
290 HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women: A Pilot Study Completed NCT03012932
291 Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens Completed NCT01944722
292 HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population Completed NCT01330147
293 European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System Completed NCT01671462
294 Integrating a Health Information Technology System With a Web-based Mobile Health Educational Intervention to Support More Effective Provider-patient Communication and HPV Vaccine Utilization Completed NCT03346915
295 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
296 A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase Human Papilloma Viruses (HPV) Vaccine Utilization and Adherence Among Adolescents in Eastern North Carolina. Completed NCT01908517
297 Adolescent Vaccination Reminders Using Email Completed NCT01732315
298 The HPV Self-test as a Test of Cure in the Follow-up of HPV-positive Women in Madagascar Completed NCT02811367
299 A Pilot Study of Immunoregulatory Factor Expression and Immune Responses in Patients With Squamous Cell Carcinoma or Papilloma of the Upper Aerodigestive Tract Completed NCT00001603
300 Establishment of a Head and Neck Cancer Tissue/Specimen Bank Completed NCT00898300
301 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
302 A Prospective Randomised Controlled Clinical Trial Investigating the Benefits of Patient-customised Headrests Versus Standard (Non-patient Specific) Headrests in the Immobilisation of Patients Receiving Radiotherapy for Head and Neck Cancer Completed NCT00973947
303 Genotypification and Predisposing Factors in Human Papilloma Virus Infection and Its Association With the Carbohydrate Antigen (CA-125) Tumoral Marker Completed NCT01924117
304 Prevalence of HPV Infection Using Self-sampling Screening and Monitoring the Earlier Impact of HPV-Vaccination Program in Switzerland Completed NCT03474211
305 Promoting HPV Vaccination Through African American Beauty Salons: a Pilot Test of a Culturally-Competent Education and Empowerment Strategy Completed NCT01461408
306 Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (Agus or Agcus) As a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia Completed NCT00003384
307 "Keeping All Teens Healthy Study": An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination Completed NCT03628885
308 HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3 Completed NCT02558803
309 Assessment of the Predictive Value of the Acetic Acid Test in Surgery Condition for the Detection of Dysplastic Lesions in Patients With Anal Condylomatosis Completed NCT03126123
310 Influence of Hpv Infections on Therapeutical Outcome of Patients Suffering From Vulvar Cancer and Ist Preinvasive Lesions Completed NCT03082950
311 Epidémiologie de l'Infection à Human Papilloma Virus Chez Les Femmes Vivant Sur Les Fleuves Maroni et Oyapock Completed NCT02895399
312 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 systemic chemotherapy
313 Immunization Delivery in Obstetrics and Gynecology Settings Completed NCT01565135
314 Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease Completed NCT00806676 Gardasil® Vaccine (FDA-approved vaccination regimen)
315 Alcohol Related Cancers and Genetic Susceptibility in Europe Follow-up - North-West England Completed NCT02049177
316 Retinoids and Intermediate Biomarkers for CIN II and III: Pilot Trial Completed NCT00003598 tretinoin
317 HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region Completed NCT03265743
318 Study of the Role of Infection by Human Papillomavirus (HPV) in the Success Rate of Pregnancies Achieved Via Medically Assisted Procreation Completed NCT01894425
319 Patient Compliance to Self-collection for Detection of HPV-DNA in Cervical Cancer Prevention: A Clinical Trial Completed NCT02431520
320 Human Papillomavirus Infection of the Mouth in Young Men and Risk Factors for Oropharyngeal Cancer Completed NCT00897273
321 A Pilot Study of Functional Mapping and Brain Perfusion Imaging in Patients Receiving Base of Skull and Brain Radiotherapy: Developing Neurocognitive Functional Organs At Risk for Individualized Conformal Radiotherapy Completed NCT00984074
322 Cryotherapy Versus Laser for the Treatment of Nongenital Cutaneous Warts: A Randomized Controlled Clinical Trial Completed NCT01808443
323 Comparison of Flocked vs. Dacron Swab for Anal Cytology, Correspondence With High Resolution Anoscopy Completed NCT00955591
324 A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury Completed NCT00897793
325 Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine Completed NCT02546752 Early Phase 1
326 Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients Completed NCT00715234
327 Text Reminders to Immunize in a Managed Care Organization Completed NCT01806714
328 Predictive Modelling for Patient Stratification According to Treatment-related Toxicity and Survival After Chemoradiation for Head and Neck Cancer Completed NCT02103010
329 Natural History of Oral Cancer Precursors Completed NCT00179361
330 Efficacy of Digital Breast Tomosynthesis (DBT) in Addition to Standard 2- Dimensional Mammography in Evaluating Extent of Disease in Newly Diagnosed Breast Cancer Patients Completed NCT03190083
331 Serum Levels of Folate And Vitamine B12 in Patients Infected With HPV and Diagnosed Atypical Squamous Cells of Undetermined Significance in Cervical Cytology Completed NCT03903952
332 Gynecological Health of Adult Women With Cystic Fibrosis: Positive Impact of the Implementation of an On-site Gynecological Consultation Completed NCT03892304
333 Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy Completed NCT01358097
334 Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life Completed NCT01181648
335 The Potential Role of Self-sampling in Women Who do Not Attend for Cervical Screening - a Randomised Controlled Trial Completed NCT00977392
336 Molecular Correlates of Response to C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck (E3303): A Phase II Trial of Eastern Cooperative Oncology Group Completed NCT01194635
337 The Effect of Human Papillomavirus Vaccination on Recurrence Rates in HIV Positive Patients Treated for Anal Condylomata Completed NCT00941889 Saline;Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
338 Using Acupuncture and Moxibustion to Promote Wellbeing and Improve Quality of Life for Patients With Upper Body Lymphoedema Secondary to Cancer Treatment Completed NCT00828516
339 A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3 in Caucasian and African-American Cancer Patients Completed NCT01015963
340 Evaluation of Normal Tissue Toxicities in Head and Neck Cancer Patients Receiving Intensity Modulated Radiotherapy (IMRT) Completed NCT00415025
341 Assessment of Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
342 The Effect of Human Papilloma Virus Genotype on Women's Sexual Life Completed NCT03837028
343 CareHPV - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas Completed NCT01539668
344 Assessment of Prevalence and Persistence of Human Papillomavirus (HPV) DNA in HIV-Infected Women Who Are Antiretroviral Naive and Have Initiated HAART Completed NCT00006444
345 Long-term Immunogenicity of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus: a Case-control Study Completed NCT02477254
346 Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis Completed NCT00970749
347 Prognostic Value of Textural Indices Extracted From Pre-therapeutic 18-F FDG PET/CT in Head and Neck Squamous Cell Carcinoma. Completed NCT03378193
348 A Three-armed Randomised Controlled Trial of Non-participants in an Organised Cervical Cancer Screening Programme Completed NCT02680262
349 A Practice-Provider-Parent-Adolescent Intervention to Increase HPV Vaccination Completed NCT03186430
350 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
351 Immunogenicity of the HPV-6, 11, 16, 18 Vaccine Among Adolescent Girls Who Receive Vaccine Doses at Non-recommended Intervals and Factors Related to Non-adherence Completed NCT01030562
352 Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients Completed NCT01663259 Cetuximab
353 Advancing New Modalities for the Detection of Oropharyngeal Cancer: Transcervical Ultrasound and HPV16 E6 Antibodies Completed NCT03226613
354 An Observational Cohort Study to Assess the Risk of Autoimmune Diseases in Adolescent and Young Adult Women Aged 9 to 25 Years Exposed to Cervarix® in the United Kingdom Completed NCT01953822
355 Research Project of the South Florida Center for Reducing Cancer Disparities (SUCCESS): Testing CHWs and HPV Self-Sampling to Increase Cervical Cancer Screening Among Minority Immigrants in Miami-Dade County: Completed NCT02121548
356 A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials Completed NCT00695422
357 Effects of Mindfulness-Based Stress Reduction (MBSR) on Immune Response to HPV Completed NCT00653146
358 Clinico-Pathological HPV DNA Typing Study of Women With Genital Warts Presenting to Groote Schuur Hospital Over a One Year Period, Evaluated by HIV Status, Psychological Impact and Costs to the Health Care System Completed NCT01192282
359 Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma. Completed NCT00937547
360 Nanopulse Efficacy Study for the Treatment of Common Warts Completed NCT02650466
361 Community Awareness, Resources and Education (CARE II): Project 3 Completed NCT01299714
362 Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings Completed NCT00002520 nicotine
363 Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening Completed NCT02265120
364 An Intervention Promoting HPV Vaccination in Safety-net Clinics Completed NCT01729429
365 HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts Completed NCT02551887
366 Prevalence and Persistence of Human Papillomavirus (HPV) and of Cervical Dysplasia in a Cohort of Women With Cystic Fibrosis Completed NCT03052556
367 Pivotal Study for Assessment of Cervical Neoplasia Using Fluorescence and Reflectance Spectroscopy Completed NCT00766701
368 Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol Completed NCT00293462
369 A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening Completed NCT01058148
370 Low-Cost Molecular Cervical Cancer Screening Study Completed NCT01231945
371 A Randomized Trial To Compare An HPV Test-And-Treat Strategy To A Cytology-Based Strategy For Prevention Of CIN 2+ In HIV-Infected Women Completed NCT01315353
372 Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County Completed NCT02067507
373 Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study Completed NCT03466710
374 Gardasil® Population-Based Condyloma Effectiveness Study In Swedish Women Including Condyloma Incidence Estimations For Swedish Men And Women Completed NCT01553994
375 Study of HPV Self Testing Evaluation in the Province of Jujuy, Argentina Completed NCT02095561
376 A Pilot Study to Introduce Male Circumcision (MC) Services to Prevent HIV Infection in Two High Prevalence Areas of the Dominican Republic (DR) Completed NCT02337179
377 Airway Intervention Registry (AIR) Extension: Recurrent Respiratory Papillomatosis Recruiting NCT03465280
378 Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge Recruiting NCT01901562
379 Effect of nd Yag Laser in Treatment of Vulval Warts Recruiting NCT03830047
380 The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy Recruiting NCT02489617
381 A Phase 2 Study of De-Intensified Risk-Adapted Postoperative Radiation Therapy for Human Papilloma Virus Associated Oropharyngeal Squamous Cell Carcinoma Recruiting NCT03875716
382 Investigation Into the Infectivity Levels of Human Papilloma Virus (HPV) in Tonsillar Tissue Recruiting NCT02841631
383 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) Recruiting NCT02072148
384 EMMI - Emättimen Mikrobiomi - Emättimen ja Suun Limakalvojen Vuorovaikutus Recruiting NCT02898818
385 Prospective, Tricentric Open Trial on the Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms Recruiting NCT03624712
386 Oral Zinc Sulfate for the Treatment of High Risk Cervical HPV Versus Placebo Recruiting NCT03404310
387 Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients Recruiting NCT03742375
388 Biomarkerscreening Via Transcriptome and Methylosome Analysis in Cervical Cancer and Its Preinvasive Lesions Recruiting NCT02238990
389 Evaluation of Controllable Infrared Bioeffect Effect for the Treatment of Cutaneous Warts After 3 Months: a Multicenter, Randomized, Open Label Controlled Trial Recruiting NCT03734003
390 Head and Neck Tumor Tissue Repository and Clinical Database Recruiting NCT00898638
391 Performance of E6/E7 mRNA to Detect Anal High-Grade Intraepithelial Lesions and Cost-effectiveness Analysis of a New Screening Strategy for Anal Cancer in HIV Positive Men Who Have Sex With Men Recruiting NCT03357991
392 A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives Recruiting NCT01931644
393 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Recruiting NCT00892866
394 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 DCF regimen
395 The Natural History of Severe Viral Infections and Characterization of Immune Defects Recruiting NCT01011712
396 Marketability of a Technology-based Intervention to Increase HPV Vaccination Recruiting NCT03497936
397 Screening for Sexually Transmitted Diseases (STDs) in Women Admitted in Family Planning, Lariboisière Hospital, for a Termination of Pregnancy: a Prospective Systematic Survey. Recruiting NCT03486522
398 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
399 Promoting Comprehensive Cervical Cancer Prevention and Better Women Health in Cameroon Recruiting NCT03757299
400 Impacting the Oral HPV Continuum: MOUTH Study (Men and Women Offering Understanding of Throat HPV) Recruiting NCT03644563
401 The Overlooked Population at Risk for AIN: Women With High-grade Lower Genital Tract Dysplasia or Cervical Cancer. Recruiting NCT01953094
402 Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions Recruiting NCT03920800
403 FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II) Recruiting NCT03853915
404 Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women Recruiting NCT02956031
405 HPV-testing of Sentinel Lymph Node Tissue From Cervical Cancer Patients. Recruiting NCT03749707
406 Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer Recruiting NCT02945631
407 Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention (REACH UP): a Feasibility Study in Women Living With HIV Recruiting NCT04155294
408 Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection Recruiting NCT02546895
409 The Natural History of GATA2 Deficiency and Related Disorders Recruiting NCT01905826
410 A Randomized Controlled Multicenter Study of Artificial Intelligence Assisted Digestive Endoscopy Recruiting NCT04071678
411 Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors Recruiting NCT03251989
412 Development of a Two-stage Cervical Cancer Screening Algorithm for Botswana Recruiting NCT03324009
413 Effects of Oral Probiotic Strains Lactobacillus Rhamnosus GR-1 and Lactobacillus Reuteri RC-14 on Prevention of GBS Vaginal Infection During Pregnancy and Influence of Postpartum Vaginal Health Condition. Recruiting NCT03688321
414 The HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California Recruiting NCT00435214
415 A Randomized Controlled Trial Comparing Cure Rates of Cervical Intraepithelial Neoplasia Grade 2 and Higher (CIN2+) Treated With CO2-based Cryotherapy, CropPen, and Thermoablation (UH3) Recruiting NCT03084081
416 A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease Recruiting NCT02904590
417 Randomized Trial Comparing Low-Dose Weekly to High-Dose Cisplatin Concurrent With Radiation for Locally Advanced Head and Neck Cancer. Recruiting NCT03649048 High-Dose Cisplatin;Low-Dose Cisplatin
418 A Randomized Multicenter Trial of Accelerated Hypo - vs. Normo-fractionated Radiotherapy for Head and Neck Squamous Cell Carcinoma (IAEA-HYPNO Trial) Recruiting NCT02765503
419 Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision (EIMC) in Sub-Saharan Africa Recruiting NCT03338699
420 The Value of HPV DNA Testing Using Self-collected Sampling in Non Attendees Cervical Cancer Screening and Molecular Triage Strategies on Self-sampled Material for HPV Positive Women. Recruiting NCT03183700
421 Social Determinants of HPV Vaccine Completion Among Adolescents Active, not recruiting NCT03709602
422 Study for the Development of Standard Operating Procedures for Anti-HPV Antibody Detection in First-void Urine: the AB-SOP Follow-up Study Active, not recruiting NCT03542227
423 The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients Active, not recruiting NCT00767897 Human Papillomavirus Vaccine
424 A Phase I Trial of IMRT With Dose-Escalated Image-Guided Stereotactic Radiosurgery (SRS) Boost for Human Papilloma Virus (HPV)- Unassociated Oropharyngeal Cancer Active, not recruiting NCT02703493
425 Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HPV HC2® Test in Women 30 Years of Age or Older Using LBC ThinPrep® Pap Test Specimens Active, not recruiting NCT02634190
426 Increasing Human Papillomavirus (HPV) Immunization Rates: The Rural Adolescent Vaccine Enterprise (RAVE) Active, not recruiting NCT03604393
427 Phase II Randomized, Double-blind, Placebo-controlled Evaluation of AHCC (Active Hexose Correlated Compound) for the Eradication of HPV Infections in Women With HPV Positive Pap Smears Active, not recruiting NCT02405533
428 trūFreeze® Spray Cryotherapy Patient Registry Active, not recruiting NCT01802203
429 Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human Active, not recruiting NCT02761122
430 Functional Outcome After Transoral Robotic Surgery (TORS) vs Oncological Treatment for Oropharyngeal Squamous Cell Carcinoma Active, not recruiting NCT03418909
431 Immune Response Evaluation to Curative Conventional Therapy of Stage III/IV Head and Neck Squamous Cell Carcinoma Patients Active, not recruiting NCT03053661
432 Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer Active, not recruiting NCT01546363
433 Improving Screening Tools to Better Predict High-Grade Anal Dysplasia for MSM Active, not recruiting NCT02816879
434 Screening HIV-Infected Women for Anal Cancer Precursors Active, not recruiting NCT01946139
435 The Ohio State University Center for Population Health and Health Disparities Community Awareness, Resources and Education (CARE II): Project 4 The PARENT (Parents in Appalachia Receive Education Needed for Teens) Project Active, not recruiting NCT01901770
436 Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging Active, not recruiting NCT03759236
437 Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination Active, not recruiting NCT02897232
438 FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation Active, not recruiting NCT02388698
439 Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators Active, not recruiting NCT03139669
440 Trial23 - Randomized Method Study on HPV-testing and Cytology Triage in Women Offered HPV-vaccination as Girls in Denmark Active, not recruiting NCT03049553
441 A Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) Active, not recruiting NCT00339989
442 Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood Enrolling by invitation NCT03638427
443 HPV Message Testing and Social Media Campaign Enrolling by invitation NCT03747302
444 High and Low Resource Interventions to Promote HPV Vaccines Enrolling by invitation NCT03824093
445 Evaluation of Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias After 3 Months: a Multicenter, Single-blind, Randomized Controlled Trial Enrolling by invitation NCT03436251
446 Implementing Cancer Prevention Using Patient-Provider Clinical Decision Support Enrolling by invitation NCT02986230
447 The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma Not yet recruiting NCT04014738
448 Survey on the Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis Followed in Cystic Fibrosis (CF) Center in France Not yet recruiting NCT03653377
449 Prevalence of HPV-associated Eye Infection and Cytokine Levels in Tears From Patients Diagnosed With Pterygium Not yet recruiting NCT04117386
450 Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Disease. A Cross-sectional Study of Vaccinal Coverage, Barriers and Motivations. Not yet recruiting NCT04180228
451 Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men Not yet recruiting NCT04154358
452 Evaluation of the Impact of a Screening Strategy Based on a Home Urinary Test in Non-respondent Women on a First Invitation to Papillomavirus Screening, on the Participation Rate Compared to a Uterine Cervix Smear Screening, With Taking Into Account the Socio-economic Level, During the Organized Screening for Cervical Cancer in Brittany Not yet recruiting NCT03598946
453 Investigating Human Papillomavirus (HPV) Infection and HPV-Associated Disease in Indian Men Who Have Sex With Men Who Are HIV-Positive Not yet recruiting NCT04142398
454 Patterns of Non-mass Enhancement of Breast MRI Using the BI-RADS Lexicon Fifth Edition With Histopathologic Correlation Not yet recruiting NCT04083027
455 Evaluation of Screening Algorithms Based on Self-collection and HPV Testing With Partial Genotyping for the Prevention of Cervical Cancer Among HIV-infected Women in Low-income Countries Not yet recruiting NCT03789513
456 Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme? Not yet recruiting NCT03975127
457 Increasing HPV Vaccination Rates Via Educational Interventions in Schools Located Within Cedars-Sinai Catchment Areas Not yet recruiting NCT03953911 Early Phase 1
458 Efficacy, Safety, Cosmesis and Patient Satisfaction With Vacuum-Assisted Percutaneous Excision (VAPE) Compared With Standard Surgical Excision (X) of Non-malignant, Borderline or High-risk Breast Lesions: A Randomized Controlled Trial Not yet recruiting NCT03868475
459 Urinary and Prostate Microbiotes and Prostate Cancer Not yet recruiting NCT03947515
460 Comparison of Cervical Intraepithelial Neoplasia 2/3 Treatment Outcomes With a Portable LMIC-adapted Thermal Ablation Device vs. Gas-based Cryotherapy Not yet recruiting NCT03429582
461 Developing and Testing a Multi-level Package of Interventions for an Integrated Care Delivery Model of HIV Prevention and Treatment Targeting Adolescent Girls in Zambia Not yet recruiting NCT03995953
462 Voice Preserving Therapy of Laryngeal Papilloma In Children Terminated NCT00591305
463 An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma Terminated NCT00017134 fenretinide
464 Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples Terminated NCT03020121
465 Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT) Terminated NCT02045186
466 Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment Terminated NCT02861404
467 Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization: Prospective Study With Virological Follow-up on 24 Months (SUIVICOL) Terminated NCT01543048
468 A Pilot Study Comparing the Effectiveness of On-site Campus Interventions to Increase the Uptake of the HPV Three-shot Series Vaccine Among College Aged Men: A 2 X 2 Repeated Design Terminated NCT02508701
469 A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension Terminated NCT01096381
470 Biomarkers of Survival in HNSCC Terminated NCT00898430
471 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide
472 Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine Withdrawn NCT00829608 Early Phase 1
473 Optical Coherence Tomography of Human Airways Withdrawn NCT00733252
474 Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults Withdrawn NCT00736216
475 Assessment of Insomnia in Patients With Head and Neck Cancer During Treatment Withdrawn NCT00616590
476 Human Papillomavirus Screening and Vaccine Readiness Program Withdrawn NCT00863096
477 Molecular Mechanisms of OSCC Tumor Invasion Withdrawn NCT00899704
478 Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men Withdrawn NCT03445416
479 Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging Withdrawn NCT01175499
480 Comparing Post-Operative Outcomes Between Gold Laser and Micro-Debriders for Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis Withdrawn NCT02900794
481 Project AWARE: Using the ED to Prevent STIs in Youth Withdrawn NCT01195220

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR

Genetic Tests for Papilloma

Anatomical Context for Papilloma

MalaCards organs/tissues related to Papilloma:

40
Breast, Skin, Cervix, Testes, Lung, T Cells, Brain

Publications for Papilloma

Articles related to Papilloma:

(showing 16604, show less)
# Title Authors PMID Year
1
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 54 61
20395210 2010
2
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 54 61
19621447 2009
3
Colonic adenoma with squamous metaplasia. 54 61
18701516 2009
4
Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. 54 61
18681909 2009
5
Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. 54 61
19411857 2009
6
FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. 54 61
19287463 2009
7
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. 54 61
19060248 2009
8
Primary adenosquamous carcinoma of the colon: report of five cases. 54 61
19562453 2009
9
Identification of human papillomavirus in esophageal squamous papillomas. 54 61
19084918 2008
10
Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? 54 61
18958930 2008
11
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. 54 61
18300235 2008
12
Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9. 54 61
17920185 2008
13
Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. 54 61
19516893 2008
14
On the mechanism of phenotypic conversion of human cervical adenocarcinoma HeLa cells surviving infection by influenza B virus: potential implications for biological management of adenocarcinomas. 54 61
18291599 2008
15
[Efficacy of local use of recombinant interferon alpha-2 preparations in combined treatment of recurrent respiratory papillomatosis]. 54 61
18833124 2008
16
Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. 54 61
18180113 2008
17
Overexpression of p27kip1 in urinary bladder urothelial carcinoma. 54 61
18036045 2007
18
Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. 54 61
17977825 2007
19
Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. 54 61
17855174 2007
20
Carotenoids suppress proliferating cell nuclear antigen and cyclin D1 expression in oral carcinogenic models. 54 61
17369034 2007
21
Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. 54 61
17638654 2007
22
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. 54 61
17116360 2007
23
The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. 54 61
17367326 2007
24
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. 54 61
17551924 2007
25
A novel mutation of PTEN gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis. 54 61
17489063 2007
26
Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. 54 61
17847937 2007
27
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. 54 61
17294450 2007
28
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. 54 61
17685229 2007
29
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). 54 61
17131388 2007
30
[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia]. 54 61
17545048 2007
31
Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 54 61
17414102 2007
32
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 54 61
17295644 2007
33
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 54 61
16698948 2007
34
Increased expression of fascin associated with malignant transformation of sinonasal inverted papilloma. 54 61
17376306 2007
35
Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. 54 61
17277618 2007
36
The history of the angiogenic switch concept. 54 61
16990761 2007
37
[Risk factors and clinical characteristic patients with vulvar cancer]. 54 61
17373116 2006
38
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 54 61
16965327 2006
39
Relationship between cyclin G1 and human papilloma virus infection in cervical intraepithelial neoplasia and cervical carcinoma. 54 61
16845792 2006
40
Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. 54 61
16624261 2006
41
Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. 54 61
16703747 2006
42
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. 54 61
16624193 2006
43
E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. 54 61
16205640 2006
44
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. 54 61
17310826 2006
45
Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells. 54 61
19771278 2006
46
Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. 54 61
16979303 2006
47
Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. 54 61
16998598 2006
48
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. 54 61
16142387 2005
49
Markers of malignant transformation of sinonasal inverted papilloma. 54 61
16005600 2005
50
Immunohistochemical evaluation of intermediate filament proteins in squamous papilloma and oral verrucous carcinoma. 54 61
16120114 2005
51
Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. 54 61
16084942 2005
52
Phosphatidylinositol 3-kinase regulates early differentiation in human laryngeal keratinocytes. 54 61
16029072 2005
53
A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. 54 61
15730517 2005
54
Papillary lesions of the breast: a molecular progression? 54 61
15770529 2005
55
Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression. 54 61
15668901 2004
56
p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. 54 61
15533911 2004
57
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. 54 61
15364449 2004
58
Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report). 54 61
15517700 2004
59
Re: Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papilloma virus (HPV) DNA detection. 54 61
15223971 2004
60
Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. 54 61
15077166 2004
61
[Correlation of E2F-1 and Rb expression with papillomatosis and ductal carcinoma in situ of the breast]. 54 61
15312366 2004
62
Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation. 54 61
15132756 2004
63
5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. 54 61
14722112 2004
64
An evaluation of Ki-67 and PCNA expression in conjunctival and eyelid tumours. 54 61
15039910 2004
65
The role of p53 codon 72 and human papilloma virus status of cutaneous squamous cell carcinoma in the Swedish population. 54 61
15844633 2004
66
How the nucleolar sequestration of p53 protein or its interplayers contributes to its (re)-activation. 54 61
15033732 2003
67
Ceramide and glutathione define two independently regulated pathways of cell death initiated by p53 in Molt-4 leukaemia cells. 54 61
12967322 2003
68
[The clinical significance of the expression of four cell cycle regulators in breast papillomotosis]. 54 61
14642081 2003
69
Epigenetic inactivation of RASSF1A in head and neck cancer. 54 61
14506151 2003
70
Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. 54 61
12960142 2003
71
Oncoprotein expression of E6 and E7 does not prevent 5-fluorouracil (5FU) mediated G1/S arrest and apoptosis in 5FU resistant carcinoma cell lines. 54 61
12792779 2003
72
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. 54 61
12801837 2003
73
Regulation of the p53 homolog p73 by adenoviral oncogene E1A. 54 61
12639967 2003
74
The nuclear localization of NFkappaB and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. 54 61
12642632 2003
75
Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function. 54 61
12497212 2003
76
P53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women. 54 61
12534455 2002
77
The roles of p53, DNA repair, and oxidative stress in ultraviolet C induction of proliferating cell nuclear antigen expression. 54 61
12485898 2002
78
Expression of the the cyclin-kinase inhibitors p21(WAF1) and p27(Kip1) and the p53 tumor suppressor genes in adult-onset laryngeal papillomas. 54 61
12434183 2002
79
UV-vulnerability of human papilloma virus type-16 E7-expressing astrocytes is associated with mitochondrial membrane depolarization and caspase-3 activation. 54 61
12442903 2002
80
Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. 54 61
12296755 2002
81
Frequent FGFR3 mutations in urothelial papilloma. 54 61
12237885 2002
82
Villoglandular papillary adenocarcinoma of the uterine cervix with immunohistochemical characteristics. 54 61
12385589 2002
83
NQO1 stabilizes p53 through a distinct pathway. 54 61
11867746 2002
84
The expression of tumorigenesis markers in oral papilloma. 54 61
12597336 2002
85
Human urinary bladder epithelial cells lacking wild-type p53 function are deficient in the repair of 4-aminobiphenyl-DNA adducts in genomic DNA. 54 61
11804609 2002
86
[A study on expression of CD44V6 and PCNA in squamous cell carcinomas]. 54 61
11840756 2001
87
Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. 54 61
11582581 2001
88
Incidence and effects of Ha-ras codon 12 G-->A transition mutations in preneoplastic lesions induced by N-nitrosomethylbenzylamine in the rat esophagus. 54 61
11568970 2001
89
Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. 54 61
11420459 2001
90
Human papillomavirus in conjunctival papilloma. 54 61
11423448 2001
91
Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis. 54 61
11422499 2001
92
Human papilloma virus and p53 expression in carcinomas associated with sinonasal papillomas: a Danish Epidemiological study 1980-1998. 54 61
11404629 2001
93
Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. 54 61
11401080 2001
94
COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. 54 61
11285227 2001
95
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis. 54 61
11277421 2001
96
[Human papilloma virus infection and expression of p16 protein in laryngeal papilloma and laryngeal carcinoma]. 54 61
12761910 2001
97
PCNA and P53 expression in relation to clinicopathological features of oral papilloma. 54 61
11820603 2001
98
Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction. 54 61
11115403 2001
99
Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. 54 61
11113868 2000
100
Lack of RB protein correlates with increased sensitivity to UV-radiation-induced apoptosis in human breast cancer cells. 54 61
11025655 2000
101
Repression of BRCA1 through a feedback loop involving p53. 54 61
10884389 2000
102
A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. 54 61
10999461 2000
103
p53 polymorphism at codon 72--does it constitute a risk for squamous intraepithelial lesions and invasive cancer of the cervix in Central Europeans? 54 61
11072671 2000
104
Molecular genetic alterations and viral presence in ophthalmic pterygium. 54 61
10851263 2000
105
Dissociation of bone morphogenetic protein-mediated growth arrest and apoptosis of mouse B cells by HPV-16 E6/E7. 54 61
10854068 2000
106
Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. 54 61
10738224 2000
107
Promoter analysis of the human ubiquitin-conjugating enzyme gene family UBE2L1-4, including UBE2L3 which encodes UbcH7. 54 61
10760570 2000
108
P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. 54 61
10775508 2000
109
Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma? 54 61
10649258 2000
110
Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1/WAF1/MDA6). 54 61
10617580 2000
111
Determination of p53-mediated transactivational ability in radiation-treated cervical cancer. 54 61
10975290 2000
112
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation. 54 61
10569807 1999
113
[Relation between human papilloma virus DNA and expressions of p53 and p21 proteins in cervical lesions]. 54 61
10639830 1999
114
Apoptosis and p53 in inverting papilloma of the sinonasal tract. 54 61
10631397 1999
115
Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination. 54 61
10373495 1999
116
p53 inactivation in chewing tobacco-induced oral cancers and leukoplakias from India. 54 61
10621843 1999
117
Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. 54 61
10212826 1999
118
Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer. 54 61
10087941 1999
119
Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. 54 61
10098744 1999
120
Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. 54 61
10459907 1999
121
Two posttranscriptional pathways that regulate p21(Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. 54 61
10047459 1999
122
Prevalence of human papilloma virus DNA in head and neck cancers carrying wild-type or mutant p53 tumor suppressor genes. 54 61
10226517 1999
123
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. 54 61
9926921 1999
124
Increased angiogenesis in the uterine cervix associated with human papillomavirus infection. 54 61
10220796 1999
125
PTHrP regulates epidermal differentiation in adult mice. 54 61
9856827 1998
126
An aggressive and invasive growth of juvenile papillomas involving the total respiratory tract. 54 61
10197157 1998
127
Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. 54 61
9833779 1998
128
p53-Independent activation of the gadd45 promoter by Delta12-prostaglandin J2. 54 61
9792828 1998
129
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. 54 61
9724636 1998
130
Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. 54 61
9754566 1998
131
Expression of p53 in normal nasal mucosa and in sinonasal papillomas with and without associated carcinoma and the relation to human papillomavirus (HPV). 54 61
9683277 1998
132
The HPV-activating cellular transcription factor Brn-3a is overexpressed in CIN3 cervical lesions. 54 61
9541499 1998
133
Differentiation-specific enhancer activity in transduced keratinocytes: a model for epidermal gene therapy. 54 61
9614560 1998
134
An ex vivo keratinocyte model for gene therapy of hemophilia B. 54 61
9242498 1997
135
Introduction of p21(Waf1/Cip1) gene into a carcinoma cell line of the uterine cervix with inactivated p53. 54 61
9215868 1997
136
Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. 54 61
9192669 1997
137
Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. 54 61
9176386 1997
138
Subcellular localization and ubiquitin-conjugating enzyme (E2) interactions of mammalian HECT family ubiquitin protein ligases. 54 61
9182527 1997
139
Presence of human papillomavirus in esophageal squamous cell carcinomas of Hong Kong Chinese and its relationship with p53 gene mutation. 54 61
9190999 1997
140
Expression of p53, Ki-67 and cytokeratin-4 (CK4) in oral papillomas. 54 61
9178172 1997
141
Relation between retinoblastoma and p53 proteins in human papilloma viruses 16/18 positive and negative cancers of the uterine cervix. 54 61
9215125 1997
142
ERC-55, a binding protein for the papilloma virus E6 oncoprotein, specifically interacts with vitamin D receptor among nuclear receptors. 54 61
9168930 1997
143
[Proliferating cell nuclear antigen in precancerous cervical disease]. 54 61
9139604 1997
144
The ubiquitin-mediated proteolytic pathway as a therapeutic area. 54 61
9020379 1997
145
[A preliminary study on p53 gene expression and infection of human papilloma virus in laryngeal squamous cell carcinoma]. 54 61
9868114 1997
146
[Antibodies against alpha-2 and gamma-interferons affect the course of juvenile respiratory papillomatosis in children treated with alpha-2 interferon preparations]. 54 61
9334008 1997
147
Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. 54 61
8985032 1996
148
p53-null cells are more sensitive to ultraviolet light only in the presence of caffeine. 54 61
8968086 1996
149
Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. 54 61
8813135 1996
150
[Combined treatment in recurrent laryngeal papillomatosis with CO2 laser microlaryngoscopic resection and interferon alpha 2b]. 54 61
9005006 1996
151
Age-dependent alterations of c-fos and growth regulation in human fibroblasts expressing the HPV16 E6 protein. 54 61
8817002 1996
152
Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. 54 61
8608985 1996
153
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. 54 61
9816227 1996
154
ras and p53 genes in male breast cancer. 54 61
8729973 1996
155
Growth suppression of a cervical cancer cell line (TMCC-1) by the human wild-type p53 gene. 54 61
8631546 1996
156
Relation between infection with human papilloma viruses and expression of p21 and p53 oncoproteins in patients with cancer of the uterine cervix. 54 61
8856306 1996
157
Human papilloma virus and P53 overexpression in carcinomas of the uterine cervix, lower uterine segment and endometrium. 54 61
8714266 1996
158
An unusual reason for obstructive sleep apnea in a boy with hemophilia B: supraglottic papilloma. 54 61
8770685 1996
159
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. 54 61
8548765 1996
160
UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation. 54 61
7478539 1995
161
CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. 54 61
7591209 1995
162
Expression of the cyclin-dependent kinase inhibitor p16 during the ongoing cell cycle. 54 61
7589458 1995
163
A human ubiquitin conjugating enzyme, L-UBC, maps in the Alzheimer's disease locus on chromosome 14q24.3. 54 61
8563171 1995
164
[Antibodies to alpha-2A interferon in children with juvenile respiratory papillomatosis]. 54 61
7502448 1995
165
Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. 54 61
7630643 1995
166
Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. 54 61
7624142 1995
167
A proteolytic pathway that recognizes ubiquitin as a degradation signal. 54 61
7615550 1995
168
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy. 54 61
7544154 1995
169
p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. 54 61
7753560 1995
170
p53 and human papilloma virus type 16 in cervical intraepithelial neoplasia and carcinoma. 54 61
8601524 1995
171
Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. 54 61
7537374 1995
172
TGF alpha and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas. 54 61
7530825 1995
173
Genetic alterations in HCA-induced tumors. 54 61
8844820 1995
174
Induction of proliferating cell nuclear antigen in cervical human papilloma virus lesions. 54 61
8001934 1994
175
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. 54 61
8058306 1994
176
Allelotype analysis of cervical carcinoma. 54 61
8044799 1994
177
HPV and p53 in urinary bladder carcinoma. 54 61
7808793 1994
178
Imprinting analysis of three genes in the Prader-Willi/Angelman region: SNRPN, E6-associated protein, and PAR-2 (D15S225E). 54 61
8004100 1994
179
The AgNOR technique, PCNA immunohistochemistry, and DNA ploidy in the evaluation of choroid plexus biopsy specimens. 54 61
7902669 1993
180
TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. 54 61
7690963 1993
181
Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. 54 61
8387914 1993
182
Laryngeal papilloma cells have high levels of epidermal growth factor receptor and respond to epidermal growth factor by a decrease in epithelial differentiation. 54 61
7679053 1993
183
Specific phosphorylation of the acidic central region of the N-myc protein by casein kinase II. 54 61
1425701 1992
184
Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. 54 61
1324797 1992
185
Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. 54 61
1381502 1992
186
The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. 54 61
1322252 1992
187
Expression of transforming growth factor alpha mRNA in benign and malignant tissues derived from gynecologic patients with various proliferative conditions. 54 61
1323947 1992
188
Desmoplastic trichilemmoma. 54 61
1373583 1992
189
Purification and characterization of a functionally homogeneous 60-kDa species of the retinoblastoma gene product. 54 61
1569054 1992
190
Specific N-methylations of HPV-16 E7 peptides alter binding to the retinoblastoma suppressor protein. 54 61
1309779 1992
191
Expression of p53 in premalignant and malignant squamous epithelium. 54 61
1717923 1991
192
Reintroduction of a normal retinoblastoma gene into retinoblastoma and osteosarcoma cells inhibits the replication associated function of SV40 large T antigen. 54 61
2064998 1991
193
Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. 54 61
1709129 1991
194
The nuclear oncoproteins: RB and p53. 54 61
2151736 1990
195
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
196
Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus. 61
31589773 2020
197
An update on systemic therapy for penile cancer. 61
31972637 2020
198
Transcriptionally Active HPV and Targetable EGFR Mutations in Sinonasal Inverted Papilloma: An Association Between Low-risk HPV, Condylomatous Morphology, and Cancer Risk? 61
31743131 2020
199
Laryngeal sequelae secondary to surgical treatment for recurrent respiratory papillomatosis in children. 61
31846823 2020
200
Intraductal sebaceous papilloma of a meibomian gland: a new entity possibly associated with the MSH6 subtype of the Muir-Torre syndrome. 61
31557488 2020
201
Health system factors influencing uptake of Human Papilloma Virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. 61
32019543 2020
202
Sudden appearance of widespread esophageal squamous papilloma with reflux esophagitis. 61
32036041 2020
203
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). 61
31851776 2020
204
Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant. 61
31707187 2020
205
Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. 61
31657099 2020
206
Anal squamous intraepithelial lesions: an update and proposed management algorithm. 61
31834554 2020
207
Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas. 61
31967480 2020
208
Membrane partitioning of peptide aggregates: coarse-grained molecular dynamics simulations. 61
30774024 2020
209
Assessment and management of B3 breast lesions with atypia: a focused review. 61
31566023 2020
210
Laryngeal Web in the Pediatric Population: Evaluation and Management. 61
31842676 2020
211
Human papilloma virus related squamous cell carcinomas of the head and neck: diagnosis, clinical implications and detection of HPV. 61
31889547 2020
212
Curing a patient of recurrent tracheal papillomatosis using laser ablation and adjuvant radiotherapy. 61
32035049 2020
213
Inverted papilloma is associated with greater radiographic inflammatory disease than other sinonasal malignancy. 61
32022422 2020
214
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma. 61
31761163 2020
215
Impact of clinical complete response on treatment outcomes in patients with locally advanced HPV-negative oropharyngeal squamous cell carcinoma. 61
31686249 2020
216
The landscape of viral associations in human cancers. 61
32025001 2020
217
Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images combined with HPV types. 61
31966086 2020
218
Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer. 61
31340702 2020
219
Strengthening health care worker engagement with early adolescence in low- and middle-income countries: an overdue area for action. 61
32031974 2020
220
A proposal for classification of oropharyngeal squamous cell carcinoma: Morphology and status of HPV by immunohistochemistry and molecular biology. 61
31465605 2020
221
Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. 61
31505033 2020
222
Multi-Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis. 61
30963598 2020
223
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. 61
31785230 2020
224
Assessing oral cancer awareness among dental and medical students of a Malaysian private university. 61
31691268 2020
225
Single nucleotide polymorphisms in transcription factor genes associated with susceptibility to oral cancer. 61
31452252 2020
226
Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis. 61
31628850 2020
227
Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study. 61
31473226 2020
228
Villitis of unknown etiology and chronic deciduitis are not associated with human papilloma virus and enterovirus infection. 61
32025822 2020
229
Virus-like particles for vaccination against cancer. 61
31456339 2020
230
Prevalence of Human Papilloma Virus in Oman; Genotypes 82, 68, 56 and 53 are dominating. 61
31935539 2020
231
A Family With A20 Haploinsufficiency Presenting With Novel Clinical Manifestations and Challenges for Treatment. 61
31977656 2020
232
Bilateral simultaneous sino-nasal inverted papilloma; A report of two cases and literature review. 61
32028092 2020
233
Clinical outcome of endonasal endoscopic prelacrimal approach in managing different maxillary pathologies. 61
31915590 2020
234
[Lymphedema-clinical picture and therapy]. 61
31912161 2020
235
Peripheral ameloblastoma of the gingiva. 61
32039059 2020
236
Upgrade rate of intraductal papilloma without atypia on breast core needle biopsy: A clinical, radiological and pathological correlation study. 61
32007236 2020
237
[Reconstruction of orbital floor defect with preserved orbital contents after advanced maxillary sinus cancer resection]. 61
31954385 2020
238
Vaccination Programs for Adults in Europe, 2019. 61
31968652 2020
239
Yaws in the Philippines: first reported cases since the 1970s. 61
31996251 2020
240
The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review. 61
31085272 2020
241
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 61
31413005 2020
242
Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy. 61
31576507 2020
243
Clinical assessment, diagnosis and management of patients with unilateral sinonasal disease. 61
31349894 2020
244
Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck. 61
31960612 2020
245
Letter to the Editor: Authors' response to letter to the Editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. 61
31788949 2020
246
Authors' response to letter to the editor, letter to the editor: Authors' response to letter to the editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. 61
31788952 2020
247
A Rare Instance of Primary Oncocytic Schneiderian Papilloma of Middle Ear and Eustachian Tube With a Combined Trans Oto and Nasal Approach Resection. 61
31977707 2020
248
Simultaneous Resection of Pituitary Macroadenoma and Sphenoid Sinus Inverted Papilloma: The Challenge of Operating Sinonasal and Skull Base Pathologies Through a Single-Stage Endoscopic Endonasal Approach. 61
31605847 2020
249
Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Improving Function While Maintaining Oncologic Outcome. 61
31961759 2020
250
Identification and chemoresistance of cancer stem cells in HPV-negative oropharyngeal cancer. 61
31897209 2020
251
Comparison of cytologic findings between specimens with and without high-risk HPV infection in those with ASC-US judgement. 61
31939005 2020
252
EBCOG position statement: Gender neutral HPV vaccination for young adults. 61
31992466 2020
253
Current Status of p16 Immunohistochemistry and HPV Testing in Fine Needle Aspiration Specimens of the Head and Neck. 61
30783052 2020
254
Crystal structure of the catalytic C-lobe of the HECT-type ubiquitin ligase E6AP. 61
31994269 2020
255
Endoscopic Submucosal Dissection of Seborrheic Keratosis-Like Lesion of the Esophagus: A New Entity? 61
30632124 2020
256
Eag1 Gene and Protein Expression in Human Retinoblastoma Tumors and its Regulation by pRb in HeLa Cells. 61
31973216 2020
257
Large pelvic mass arising from the cervical stump: A case report. 61
31970181 2020
258
Squamous cell carcinoma associated with inverted papilloma: Recurrence and prognostic factors. 61
31885722 2020
259
Giant Choroid Plexus Papilloma Resection Utilizing a Transcollation System. 61
31065711 2020
260
Human papilloma virus genotypes in dysplasia and epithelial hyperplasia of oral cavity using the luminex xmap technology. A multicenter study. 61
31880291 2020
261
Clinico-pathological peculiarities of human papilloma virus driven head and neck squamous cell carcinoma: A comprehensive update. 61
32007572 2020
262
Epidermal ROCK2-induces AKT1/GSK3β/β-catenin, NFκB and dermal tenascin-C; but enhanced differentiation and p53/p21 inhibit papilloma. 61
31907522 2020
263
Cervicovaginal Microbiome and Urine Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with Human Papilloma Virus Infections. 61
31952112 2020
264
Human papilloma virus-related premalignant and malignant lesions of the cervix and anogenital tract in immunocompromised women. 61
32039466 2020
265
Awareness and knowledge of human papilloma virus in UK women aged 25 years and over: Results from a cross-sectional internet-based survey. 61
31639253 2020
266
Use of intralesional cidofovir in the recurrent respiratory papillomatosis: a review of the literature. 61
32017003 2020
267
Evaluation of Safety of Intralesional Cidofovir for Adjuvant Treatment of Recurrent Respiratory Papillomatosis. 61
31895450 2020
268
Direct cholangioscopy for diagnosis and treatment guidance of suspected biliary papillomatosis with malignant transformation. 61
31398736 2020
269
International Pediatric Otolaryngology Group (IPOG): Juvenile-onset recurrent respiratory papillomatosis consensus recommendations. 61
31698245 2020
270
Evaluation of Vascular Patterns Using Contact Endoscopy and Narrow-Band Imaging (CE-NBI) for the Diagnosis of Vocal Fold Malignancy. 61
31968528 2020
271
Bioremediation of soils saturated with spilled crude oil. 61
31980664 2020
272
Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report. 61
31610441 2020
273
[Angiolytic laser applications for the larynx : Phonosurgical concepts for transoral laser microsurgery]. 61
31950226 2020
274
Profile of Laryngeal Microsurgeries in Patients Over 60 Years Old. 61
31929834 2020
275
The Use of 532-Nanometer-Pulsed Potassium-Titanyl-Phosphate (KTP) Laser in Laryngology: A Systematic Review of Current Indications, Safety, and Voice Outcomes. 61
31928082 2020
276
Abnormal Activation of Myeloid Dendritic Cells in JORRP Patients and Associated with Disease Activity. 61
31726188 2020
277
US Medical Trainees' Knowledge of Human Papilloma Virus and Head and Neck Cancer. 61
31661360 2020
278
Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. 61
31771962 2020
279
Skin colonization with beta papilloma virus drives tissue immunity and resistance to squamous cell cancer. 61
31749172 2020
280
Glandular-type inverted papilloma of urinary bladder - Report of a unique case with immunohistochemistry. 61
32031131 2020
281
Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. 61
32003459 2020
282
Invasive squamous cell carcinoma arising in an inverted papilloma involving oral cavity. 61
31989404 2020
283
Efficacy of intralesional methotrexate in the treatment of plantar warts. 61
31965678 2020
284
Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution's Experience. 61
31991753 2020
285
Fertility-preserving local excision under a hysteroscope with combined chemotherapy in a 6-year-old child with clear cell adenocarcinoma of the cervix: A case report and review of the literature. 61
32000369 2020
286
[Development of a squamous cell carcinoma of the urinary bladder after intravesical condylomas]. 61
31940665 2020
287
Cannabinoids promote progression of HPV positive head and neck squamous cell carcinoma via p38 MAPK activation. 61
31932491 2020
288
Acoustofluidic Salivary Exosome Isolation: A Liquid Biopsy Compatible Approach for Human Papillomavirus-Associated Oropharyngeal Cancer Detection. 61
31843276 2020
289
Cervical cytology reproducibility and associated clinical and demographic factors. 61
31639288 2020
290
HPV-related oropharyngeal cancer prevalence in a middle eastern population using E6/E7 PCR. 61
31921331 2020
291
Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines. 61
31936595 2020
292
Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. 61
31939101 2020
293
Value of pre- and intraoperative diagnostic methods in suspected glottic neoplasia. 61
31654182 2020
294
Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. 61
32013270 2020
295
SEOM clinical guidelines for cervical cancer (2019). 61
31981078 2020
296
Choroid Plexus Carcinoma in Adults: Literature Review and First Report of a Location into the Third Ventricle. 61
31629149 2020
297
Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. 61
31566705 2020
298
Anti-HPV Nanoemulsified-Imiquimod: A New and Potent Formulation to Treat Cervical Cancer. 61
31907712 2020
299
Suppression of HIF-1α accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer. 61
31948750 2020
300
Prevalence of human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer in imprisoned women worldwide: a systematic review and meta-analysis. 61
31649041 2020
301
Increase in IL-17-positive cells in sinonasal inverted papilloma. 61
31623021 2020
302
[Surgical strategy for resection of sinonasal inverted papilloma]. 61
31954382 2020
303
Impact of HPV Immunization Training on Dental Hygiene Students' Attitudes and Confidence Regarding HPV Preventive Education. 61
31977100 2020
304
Men having sex with men and the HPV vaccine in France: A low vaccine coverage that may be due to its infrequent proposal by physicians. 61
32008880 2020
305
Improvement in RNA quantity and quality in cervico-vaginal cytology. 61
31959186 2020
306
Human Papillomavirus and Factors Associated with Recurrence in Sinonasal Inverted Papillomas from Poland and Spain. 61
31916205 2020
307
The incidence of oropharyngeal cancer and rate of human papillomavirus vaccination coverage in Florida, 2011 through 2015. 61
31902400 2020
308
Role of human papillomavirus in laryngeal squamous cell carcinoma: A meta-analysis of cohort study. 61
31733044 2020
309
p16 Positive Histologically Bland Squamous Metaplasia of the Cervix: What does It Signify? 61
31498174 2020
310
Laryngotracheobronchial papillomatosis: an uncommon cause of recurrent respiratory infection. 61
31994672 2020
311
Himachalol induces apoptosis in B16-F10 murine melanoma cells and protects against skin carcinogenesis. 61
31918014 2020
312
Medical practitioners' educational competence about oral and oropharyngeal carcinoma: a systematic review and meta-analysis. 61
31785865 2020
313
Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome. 61
31652152 2020
314
The AP-1 pathway; A key regulator of cellular transformation modulated by oncogenic viruses. 61
31788897 2020
315
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. 61
31984480 2020
316
Maxillary mesenchymal chondrosarcoma leading to a diagnosis of Li-Fraumeni syndrome. 61
31976063 2020
317
RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis. 61
32001819 2020
318
Papilloma diagnosed on core biopsies has a low upgrade rate. 61
31864203 2019
319
Benign tumours and tumour-like lesions in the oral cavity: a retrospective analysis. 61
31998005 2019
320
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer. 61
31600090 2019
321
Human Orf: An Under-recognized Entity. 61
31969245 2019
322
A case of cervical adenocarcinoma arising from endometriosis in the absence of human papilloma virus infection. 61
31883176 2019
323
Altered microRNA processing proteins in HPV-induced cancers. 61
31408800 2019
324
Usefulness Analysis of Urine Samples for Early Screening of Human Papilloma Virus Infection. 61
31950024 2019
325
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA). 61
31904021 2019
326
Role of Electron Microscopy in Early Detection of Altered Epithelium During Experimental Oral Carcinogenesis. 61
30867083 2019
327
Benign breast papillary lesions diagnosed on core biopsy: upgrade rate and risk factors associated with malignancy on surgical excision. 61
31372738 2019
328
The evolving landscape of HPV-related neoplasia in the head and neck. 61
31654690 2019
329
A case of papilloma-like lesions of the esophagus in Cronkhite-Canada syndrome. 61
31901311 2019
330
Target DNA detection of human papilloma virus-16 E7 gene by capture-target-reporter sandwich on interdigitated electrode sensor. 61
31493451 2019
331
Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment. 61
31430574 2019
332
High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis. 61
31446060 2019
333
Efficacy of microsurgery in combined with topical-PDT in treating recurrent respiratory papillomatosis: compare JORRP with AORRP. 61
31556770 2019
334
Successful Orthotopic Liver Transplant for Diffuse Biliary Papillomatosis With Malignant Transformation: A Case Report With Long-Term Follow-Up. 61
29534660 2019
335
One-step detection of human papilloma viral infection using quantum dot-nucleotide interaction specificity. 61
31450441 2019
336
The role of human papilloma virus test in men: First exhaustive review of literature. 61
31874781 2019
337
Sinonasal Oncocytic Papilloma-A Series of 20 Cases With Special Emphasis on Recurrences. 61
31890872 2019
338
ErbB1 and ErbB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China. 61
31556771 2019
339
Activation of anthraquinone biosynthesis in long-cultured callus culture of Rubia cordifolia transformed with the rolA plant oncogene. 61
31526834 2019
340
Role of epstein-barr virus in the severity of recurrent respiratory papillomatosis. 61
31860132 2019
341
Synthesis and Evaluation of Anisomelic acid-like Compounds for the Treatment of HPV-Mediated Carcinomas. 61
31889069 2019
342
Odontogenic sinusitis is a common cause of unilateral sinus disease with maxillary sinus opacification. 61
31529785 2019
343
[Socio-demographic characteristics, indicators of risk and health care in relation to sexual transmission infections in migrant population of Granada]. 61
31782411 2019
344
The Preventive Effect of Dietary Antioxidants Against Cervical Cancer Versus the Promotive Effect of Tobacco Smoking. 61
31847279 2019
345
Refractory epilepsy associated with ventriculoperitoneal shunt over-drainage: case report. 61
31492981 2019
346
Postoperative multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intravenous doxycycline and intraventricular gentamicin: A case report. 61
31911917 2019
347
Temporal Horn Choroid Plexus Papilloma Presenting with Seizures in Adulthood: Clinical Case Report and Review of the Literature. 61
31493601 2019
348
Clinical Controversies in Cervical Cancer Screening. 61
31305485 2019
349
Melatonin: A new inhibitor agent for cervical cancer treatment. 61
31131897 2019
350
Role of ganglioside biosynthesis genetic polymorphism in cervical cancer development. 61
31847655 2019
351
Rare and unusual case of familial focal dermal hypoplasia (Goltz syndrome) presenting to otolaryngology in the UK. 61
31811108 2019
352
Tumors of the conjunctiva and cornea. 61
31755426 2019
353
[Current Standard of Care in Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Prevention, diagnostics, prognostication and therapy]. 61
31791073 2019
354
Clinical Implications of Carcinoma In Situ in Sinonasal Inverted Papilloma. 61
31635524 2019
355
Cervicovaginal Müllerian papilloma malignant transformation in a prepubertal girl. 61
31345936 2019
356
Low prevalence of human papillomavirus infection in sinonasal inverted papilloma and oncocytic papilloma. 61
31797088 2019
357
Esophageal Papilloma Detected by Positron Emission Tomography. 61
31866626 2019
358
Solitary Endobronchial Papilloma: A Rare Entity. 61
31779763 2019
359
For HPV self-sampling, stated willingness does not correspond with subsequent uptake by rural Malawian women. 61
31860554 2019
360
Analysis of HPV genotype-specific concordance between EUROArray HPV and HPV 3.5 LCD-Array Kit in cervical samples of 163 patients. 61
31875249 2019
361
The changing landscape of head and neck cancer radiotherapy patients: is high-risk, prolonged feeding tube use indicative of on-treatment weight loss? 61
31385650 2019
362
Reducing indications for radial scar surgical excision in Slovenian breast cancer screening program. 61
31927469 2019
363
Application of radiomics for the prediction of HPV status for patients with head and neck cancers. 61
31853980 2019
364
Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases. 61
31869000 2019
365
Assessment of HPV 16, HPV 18, p16 expression in advanced stage laryngeal cancer patients and prognostic significance. 61
31899126 2019
366
[Value of Diffusion-weighted Imaging and Apparent Diffusion Coefficient in the Differential Diagnosis of Posterior Fossa Solid Hemangioblastoma]. 61
31907124 2019
367
Gingival Papillomatosis as the Oral Sign of Cowden Syndrome: A Case Report. 61
31969239 2019
368
Lack of Uptake of Prophylactic Human Papilloma Virus Vaccine Among Women With Systemic Lupus Erythematosus Seen at a Regional Medical Center. 61
31764496 2019
369
Acceptance of Self-Sampling Among Long-Term Cervical Screening Non-Attenders with HPV-Positive Results: Promising Opportunity for Specific Cancer Education. 61
31522376 2019
370
Cost-benefit analysis of a projected national human papilloma virus vaccination programme in Lebanon. 61
31774137 2019
371
Clinicopathological study of ameloblastoma and detection of human papilloma virus by immunohistochemistry. 61
31777517 2019
372
Squamous Cell Papilloma in a Student Aviator. 61
31666160 2019
373
Evaluation of diagnosed cases of eye rhinosporidiosis in a public hospital of Maranhão, Northeast Brazil. 61
31703563 2019
374
[Knowledge of German-speaking urologists regarding the association between penile cancer and human papilloma virus: results of a survey of the European PROspective Penile Cancer Study (E-PROPS)]. 61
31745963 2019
375
Resection of inverted papilloma in nasal cavity with transseptal access and crossing multiple incisions minimizes bleeding and reveals the tumor pedicle. 61
31732283 2019
376
Association between interleukin-2, interleukin-10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions. 61
31612062 2019
377
Prevalence of Human Papilloma Virus Sub Genotypes following Head and Neck Squamous Cell Carcinomas in Asian Continent, A Systematic Review Article. 61
31759348 2019
378
A Phase 2 Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed After Transoral Robotic Surgery for Human Papilloma Virus-Related Squamous Cell Carcinoma of the Oropharynx. 61
31785337 2019
379
High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate- to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex With Men in Low-to-Absent Cytological Abnormalities. 61
30770528 2019
380
[Inverted Variant of Urothelial Carcinoma of the Urinary Bladder : A Case Report]. 61
31902180 2019
381
An Immunocompetent Mouse Model of HPV16(+) Head and Neck Squamous Cell Carcinoma. 61
31693903 2019
382
Epigenetic Modifications in Head and Neck Cancer. 61
31712935 2019
383
Update on Neuroendocrine Carcinomas of the Larynx. 61
31415081 2019
384
Recurrence of benign phonotraumatic vocal fold lesions after microlaryngoscopy. 61
31693179 2019
385
Spontaneous oral tumours in 18 rabbits (2005-2015). 61
31737910 2019
386
Congenital Giant Folliculosebaceous Cystic Hamartoma of Thigh: A Rare Case. 61
31896850 2019
387
"Read" and 'Tailor' Your Treatment. 61
31857982 2019
388
Integration rates of human papilloma virus genome in a molecular survey on cervical specimens among Iranian patients. 61
30444753 2019
389
Incidental Histopathologic Finding of Sinonasal Inverted Papilloma Among Surgically Excised Polyps Increases the Risk of Tumor Recurrence. 61
31763267 2019
390
High CT attenuation values relative to the brainstem may predict squamous cell carcinoma arising from inverted papilloma. 61
31498015 2019
391
Does evaluation of tumor volume or/both origination site better guide to optimal surgery for inverted papilloma? 61
31870739 2019
392
Surgery of Inverted Papilloma of the Maxillary Sinus via Translacrimal Approach-Long-Term Outcome and Literature Review. 61
31694225 2019
393
Vocal cord surgery and pharmacological treatment of a patient with HPV and recurrent respiratory papillomatosis. 61
31732543 2019
394
Inverted Sinonasal Papilloma Involving the Middle Ear with Evidence of Squamous Cell Carcinoma. 61
31890383 2019
395
Surgical Management of a Recurrent Orbit-Eroding Mucocele Associated With Frontal-Ethmoidal Sinus Inverted Papilloma. 61
31567913 2019
396
Endoscopic Resection of Sinonasal Inverted Papilloma: A Multivariate Retrospective Analysis of Factors Affecting Recurrence and Persistence. 61
31777289 2019
397
Oropharyngeal Squamous Cell Carcinoma: Human Papilloma Virus Coinfection with Streptococcus anginosus. 61
31800758 2019
398
Stathmin and EGFR correlates to HPV status and clinical outcome in sinonasal inverted papilloma. 61
31710049 2019
399
Overexpression of FoxM1 in Sinonasal Inverted Papilloma and Associated Squamous Cell Carcinoma. 61
31333047 2019
400
Sinonasal Inverted Papilloma: Efficacy of Demucosation to Reduce Recurrence After Surgical Managements. 61
31763318 2019
401
Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model 61
31104420 2019
402
TLR9 EXPRESSION, LANGERHANS CELL DENSITY AND LYMPHOCYTIC INFILTRATION IN PROGRESSING CERVICAL INTRAEPITHELIAL NEOPLASIA. 61
31889719 2019
403
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. 61
31727874 2019
404
Mitochondrial somatic mutations and the lack of viral genomic variation in recurrent respiratory papillomatosis. 61
31719597 2019
405
Comparison of Familial Clustering of Anogenital and Skin Cancers Between In Situ and Invasive Types. 61
31695117 2019
406
Improving exposure for transoral oropharyngeal surgery with the floor of mouth window: a cadaveric feasibility study. 61
31718714 2019
407
Morphology, p16, HPV, and outcomes in squamous cell carcinoma of the penis: a multi-institutional study. 61
31698006 2019
408
Human papillomavirus and infiltration of CD8- and Foxp3-positive immune cells in sinonasal inverted papillomas. 61
31486701 2019
409
Can we see what is invisible? The role of MRI in the evaluation and management of patients with pathological nipple discharge. 61
31352554 2019
410
Trends and targets in antiviral phototherapy. 61
31397467 2019
411
Distinct migratory pattern of naive and effector T cells through the blood-CSF barrier following Echovirus 30 infection. 61
31752904 2019
412
Second primary anal and oropharyngeal cancers in cervical cancer survivors. 61
31128108 2019
413
Next generation DNA sequencing of atypical choroid plexus papilloma of brain: Identification of novel mutations in a female patient by Ion Proton. 61
31612017 2019
414
Immigration, screening, and cervical cancer incidence: an application of Age-Period-Cohort analysis. 61
30431461 2019
415
Analyzing Awareness on Risk Factors, Barriers and Prevention of Cervical Cancer among Pairs of Nepali High School Students and Their Mothers. 61
31717567 2019
416
Cofactors and Their Association with Cancer of the Uterine Cervix in Women Infected with High-Risk Human Papillomavirus in South India. 61
31759367 2019
417
Fourth ventricle papilloma and intractable cough. 61
31745847 2019
418
Absence of high-risk human papilloma virus in p16 positive inverted sinonasal papilloma. 61
31732387 2019
419
Detection and genomic characterization of Bovine papillomavirus isolated from Chinese native cattle. 61
31269541 2019
420